Butyrophilin molecules govern γδ T cell reactivity against phosphoantigens
作者
Marc Rigau,Simone Ostrouska,Tom Fulford,Darryl N. Johnson,Katherine Woods,Zheng Ruan,Hamish E. G. McWilliam,Christopher Hudson,Candani S. A. Tutuka,Adam K. Wheatley,Stephen John Kent,Jóse A. Villadangos,Bhupinder Pal,Christian Kurts,Jason Simmonds,Matthias Pelzing,Andrew Hammet,Anne M. Verhagen,Gino Vairo,Eugene Maraskovsky
出处
期刊:Journal of Immunology [American Association of Immunologists] 日期:2020-05-01卷期号:204 (1_Supplement): 140.12-140.12
标识
DOI:10.4049/jimmunol.204.supp.140.12
摘要
Abstract Humans have a minor lymphocyte population of gamma-delta (γδ) T cells. The majority of these express a recombined Vγ9Vδ2 T cell receptor (TCR) attractive to immunotherapy. This distinct TCR conveys reactivity to phosphorylated antigens (pAg) that derive from pathogens or accumulate inside tumour cells. Such T cell responses are regulated by butyrophilin (BTN) 3A1 and other membrane-related proteins present on antigen-presenting cells. However, the activation mechanism and direct molecular ligand recognised by the γδ TCR remain a crucial unresolved question. Herein, we used pAg-reactive TCR probes in a whole-genome screen to identify BTN2A1 as an essential ligand. In further investigation, we elucidated its functionality working in cis with BTN3A1. Also, a mutational analysis unveiled critical regions of the γδ TCR are positioned at opposite sides. We locate germ-line encoded residues of the Vγ9 chain were responsible for BTN2A1 binding, whereas two amino-acids of the Vδ2 chain were necessary for a complete response to pAg. In conclusion, we propose a dual-ligand complex model that senses pAg to evoke immune responses, wherein BTN2A1 sets the framework to develop new opportunities on γδ T cell-based immunotherapies.